Will oversee partnerships with life sciences, biopharma, and biotech
CAMBRIDGE, Mass.–(BUSINESS WIRE)–Iterative Scopes, a pioneer in precision-medicine technologies for gastroenterology, announced today that Laura Mantell has joined its leadership team as Vice President of Life Sciences.
“Laura brings to us a wealth of experience in the healthtech space, having spent the last decade leading and growing some of the most impactful startups in healthcare,” said Jonathan Ng, founder and CEO of Iterative Scopes. “Having gotten to know Laura over the past year, I know that she not only brings onboard deep knowledge of the healthcare industry, but is also a great fit for the culture and team that we are building here at Iterative Scopes.”
As Vice President of Life Sciences at Iterative Scopes, Mantell will steer all life sciences, biopharma, and biotech partnerships—including new, existing, and growing business. She will play a critical role in Iterative Scopes’ work to optimize clinical trials, advance therapies to market, and improve patient outcomes.
Prior to joining Iterative Scopes, Mantell led the digital health team at Ribbon Health, a series-B startup building an API layer for healthcare enterprises. Before that, she was a Principal at Flatiron Health (now a member of the Roche Group), where she helped build and scale the life sciences organization as an early member of the team.
“Iterative Scopes is leading the way in a new and growing space, and I’m so excited to join the team,” says Mantell. “This position and organization offer a tremendous new opportunity to use technology to increase recruitment for clinical trials, streamline provider workflows, and improve patient care. I look forward to partnering with providers, EHR systems, and life sciences companies, as well as working with my Iterative Scopes colleagues, to generate important insights that will accelerate drug development and R&D in the field.”
About Iterative Scopes
Iterative Scopes is a pioneer in the application of artificial intelligence-based precision medicine for gastroenterology with the aim of helping to optimize clinical trials investigating treatment of inflammatory bowel disease (IBD). The technology is also designed to potentially enhance colorectal cancer screenings. Its powerful, proprietary artificial intelligence and computer vision technologies have the potential to improve the accuracy and consistency of endoscopy readings. Iterative Scopes is initially applying these advances to impact polyp detection for colorectal cancer screenings and working to standardize disease severity characterization for inflammatory bowel disease. Longer term, the company plans to establish more meaningful endpoints for GI diseases, which may be better predictors of therapeutic response and disease outcomes. Spun out of MIT in 2017, the company is based in Cambridge, Massachusetts.
Ariel Rapoport, Associate Director of Marketing